Prilenia to Present Latest Research from its Pridopidine Programs for Huntington Disease and ALS at AAN 2024
Prilenia Plans to Submit MAA in the EU for Pridopidine in Huntington’s Disease
Prilenia Announces Data in Support of Plans to Initiate Phase 3 Study in ALS
Prilenia Achieves Last Patient Last Visit in Phase 3 PROOF-HD Clinical Study for Huntington’s Disease
Prilenia Announces Topline Results for Pridopidine in Phase 2 ALS Study
Prilenia Therapeutics’ amyotrophic lateral sclerosis (ALS) therapy did not improve disease severity, but the biotech is pointing to “positive trends” from an exploratory analysis, suggesting that some patients' experienced a slower decline.
NAARDEN, Netherlands & WALTHAM, Mass.--(BUSINESS WIRE)--Prilenia Therapeutics B.V., a clinical stage biotechnology company focused on the urgent mission to develop novel therapeutics to slow the progression of neurodegenerative and neurodevelopmental disorders, today announced the appointment of Anne Sullivan as Chief Business Officer. In this role, Ms. Sullivan will lead all strategic collaboration activities.
NAARDEN, The Netherlands--(BUSINESS WIRE)--Prilenia Therapeutics B.V., a clinical stage biotech company focused on developing novel treatments for neurodegenerative and neurodevelopmental disorders, today announced the completion of participant enrollment in the pridopidine arm of the HEALEY ALS Platform Trial. The trial is led by the Sean M. Healey & AMG Center for ALS at Massachusetts General Hospital and is designed to evaluate the safety and efficacy of multiple drug candidates in people with Amyotrophic Lateral Sclerosis (ALS).
NAARDEN, Netherlands--(BUSINESS WIRE)--Prilenia Therapeutics B.V., a clinical stage biotech company focused on developing novel treatments for neurodegenerative and neurodevelopmental disorders, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to pridopidine for development as a potential treatment for Huntington’s Disease (HD).
Even while serving as the global R&D head for Teva several years ago, Michael Hayden had high hopes for a drug known as pridopidine. But he wasn’t always on the right track.